Gossamer Bio (NASDAQ:GOSS) versus Quantum Biopharma (NASDAQ:QNTM) Head-To-Head Analysis

Quantum Biopharma (NASDAQ:QNTM) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Volatility & Risk

Quantum Biopharma has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500.

Earnings and Valuation

This table compares Quantum Biopharma and Gossamer Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17 million	($5.49)	-0.56
Gossamer Bio	$48.47 million	0.82	-$170.37 million	($0.70)	-0.24

Quantum Biopharma has higher earnings, but lower revenue than Gossamer Bio. Quantum Biopharma is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Comparatively, 3.7% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Quantum Biopharma and Gossamer Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-582.23%	-184.20%
Gossamer Bio	-235.00%	N/A	-112.04%

Analyst Recommendations

This is a summary of current recommendations and price targets for Quantum Biopharma and Gossamer Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1	0	0	0	1.00
Gossamer Bio	2	3	4	0	2.22

Gossamer Bio has a consensus price target of $3.20, indicating a potential upside of 1,781.25%. Given Gossamer Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Quantum Biopharma.

Summary

Gossamer Bio beats Quantum Biopharma on 10 of the 13 factors compared between the two stocks.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.